Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NE3107 in Mild Cognitive Impairment and Mild Dementia
NCT05227820Phase 2Completed
- Sponsor
- Neurological Associates of West Los Angeles
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bezisterim in Alzheimer's disease (AD), sponsored by Neurological Associates of West Los Angeles. Primary endpoint: Change in fMRI at 3 months. Started Jan 2022; status: completed.
02
Drugs
bezisterim
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05227820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227820.